{"id":575825,"date":"2025-02-11T00:00:00","date_gmt":"2025-02-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2025-biopharma-breast-cancer-current-treatment-physician-insights-us-2025\/"},"modified":"2026-04-27T23:19:20","modified_gmt":"2026-04-27T23:19:20","slug":"cutron0009-2025-biopharma-breast-cancer-current-treatment-physician-insights-us-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2025-biopharma-breast-cancer-current-treatment-physician-insights-us-2025\/","title":{"rendered":"Breast Cancer | Current Treatment: Physician Insights | US | 2025"},"content":{"rendered":"<p>The breast cancer treatment landscape is rapidly evolving. CDK4\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio) plus endocrine therapy are entrenched first-line treatments for metastatic HR-positive \/ HER2-negative disease; this drug class moved to the early-stage setting with the approval of adjuvant Verzenio in 2021. Biomarker-driven therapies\u2014including Menarini Group\u2019s Orserdu (ESR1-mutant), Novartis\u2019s Piqray (PIK3CA-mutant), and AstraZeneca\u2019s Truqap (PIK3CA\/AKT1\/PTEN-mutant)\u2014have expanded treatment options for metastatic HR-positive \/ HER2-negative disease. Meanwhile, Merck &#038; Co.\u2019s Keytruda has changed the treatment paradigm for certain patients with early and metastatic triple-negative breast cancer. PARP inhibitors (AstraZeneca \/ Merck &#038; Co.\u2019s Lynparza, Pfizer\u2019s Talzenna) are an option for PARP-mutant patients with either triple-negative or HR-positive \/ HER2-negative disease; for these two subtypes, the approval of next-generation ADCs (Gilead&#8217;s Trodelvy, Daiichi Sankyo \/ AstraZeneca\u2019s Enhertu for HER2-low) has diversified therapy options for metastatic patients. In the HER2-positive metastatic setting, Enhertu\u00b4s label expansion to the second line is redefining treatment.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment rates for breast cancer by key subtype and line of therapy?<\/li>\n<li>What are physician-reported testing rates for select biomarkers (e.g., mutations in PIK3CA, ESR1, and PARP; HER2-low and PD-L1 expression) in relevant breast cancer subtypes?<\/li>\n<li>What is the patient share of key drugs and regimens by type of breast cancer?<\/li>\n<li>What are the main drivers of and key obstacles to the uptake of select therapies?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul>\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 100 medical oncologists in the United States fielded in December 2024.<\/p>\n<p><strong>Key drugs: <\/strong>IIbrance, Kisqali, Verzenio, Lynparza, Talzenna, Piqray, Enhertu, Orserdu, Truqap, Trodelvy, Phesgo.<\/p>\n","protected":false},"template":"","class_list":["post-575825","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575825\/revisions"}],"predecessor-version":[{"id":577522,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575825\/revisions\/577522"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=575825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}